I-Lenvatinib Mesylate Intermediate CAS 205448-65-3 Ubumsulwa >98.0% (HPLC) Factory
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
I-Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
I-Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama Lekhemikhali | I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
Omqondofana | I-1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;I-7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;I-Lenvatinib Intermediate 3 |
Inombolo ye-CAS | 205448-65-3 |
Inombolo yeCAT | I-RF-PI1973 |
Isimo Sesitoko | Esitokweni, Amandla Okukhiqiza 50 MT/Unyaka |
I-Molecular Formula | I-C12H11NO4 |
Isisindo samangqamuzana | 233.22 |
Iphuzu elibilayo | 421.0±45.0℃ |
Ukuminyana | 1.267±0.060 g/cm3 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Off-White to Yellowish Powder |
Ukuhlanzeka / Indlela Yokuhlaziya | >98.0% (HPLC) |
Ukulahlekelwa Ekumisweni | <1.00% |
Izinsalela ekushiseni | <0.50% |
Ukungcola Okuphelele | <2.00% |
H-NMR | Ivumelana Nesakhiwo |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | Pharmaceutical Intermediates |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) iphakathi kwe-Lenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib, ethengiswa ngaphansi kwegama lomkhiqizo elithi Lenvima phakathi kokunye, umuthi wokulwa nomdlavuza wokwelapha izinhlobo ezithile zomdlavuza wegilo kanye neminye imidlavuza.Yakhiwe yi-Eisai Co. futhi isebenza njenge-multiple kinase inhibitor ngokumelene ne-VEGFR1, VEGFR2 kanye ne-VEGFR3 kinases.I-Lenvatinib ivunyelwe (kusukela ngo-2015) yokwelashwa komdlavuza we-thyroid ohlukile ophindeka endaweni noma we-metastatic, oqhubekayo, futhi ongaphenduli ekwelashweni nge-radioiodine (radioiodine).NgoMeyi 2016, i-US Food and Drug Administration (FDA) yagunyaza (ngokuhambisana ne-everolimus) ukuze zelashwe i-renal cell carcinoma ethuthukisiwe kulandela ukwelashwa okukodwa kwangaphambili kokulwa ne-angiogenic.Umuthi ugunyazwe nase-US nase-European Union nge-hepatocellular carcinoma engakwazi ukususwa ngokuhlinzwa ezigulini ezingazange zithole ukwelashwa komdlavuza ngomlomo noma ngomjovo.